Esperion announce common stock offering, no amount given

Esperion Therapeutics announced that it has commenced an underwritten public offering of shares of its common stock. All shares to be sold in the proposed offering of common stock will be sold by Esperion. Esperion intends to use the net proceeds from the offering of common stock, together with its existing cash and cash equivalents, to fund the ongoing commercialization efforts for NEXLETOL and NEXLIZET, research and clinical development of current or additional pipeline candidates, working capital, capital expenditures, and general corporate purposes. Jefferies is acting as sole book-running manager for the offering.